Introduction:
The biosimilar market in Ireland is experiencing significant growth, reflecting the global trend towards increased adoption of biosimilars. In 2025, the global biosimilar market was valued at $5.7 billion, with a CAGR of 35%. Ireland, known for its strong pharmaceutical industry, has emerged as a key player in the biosimilar market. With a focus on innovation and quality, Ireland is home to several major biosimilar developers leading the way in the industry.
Top 50 Major Biosimilar Developers in Ireland 2026:
1. Pfizer Ireland Pharmaceuticals
2. AbbVie Biotechnology Ireland
3. MSD Ireland (Merck)
4. Amgen Ireland
5. Janssen Sciences Ireland
6. Roche Ireland
7. Bristol-Myers Squibb Cruiserath Biologics
8. Eli Lilly and Company (Ireland)
9. Novartis Ireland
10. Takeda Ireland
11. Boehringer Ingelheim Ireland
12. Biogen Idec Limited
13. Eisai Ireland
14. Genzyme Ireland
15. Gilead Sciences Ireland
16. Ipsen Ireland
17. Mallinckrodt Pharma Ireland
18. Sanofi-Aventis Ireland
19. Sobi Ireland
20. Teva Pharmaceuticals Ireland
Insights:
The biosimilar market in Ireland is expected to continue its growth trajectory, driven by factors such as increasing demand for cost-effective treatment options and patent expirations of biologic drugs. By 2026, the global biosimilar market is projected to reach $23.8 billion, with Ireland playing a significant role in this growth. As biosimilar developers in Ireland continue to innovate and expand their portfolios, the country is poised to remain a key player in the global biosimilar market. With a focus on quality and compliance, Irish companies are well-positioned to meet the growing demand for biosimilars worldwide.
Related Analysis: View Previous Industry Report
